Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 14, 2017; 23(14): 2519-2526
Published online Apr 14, 2017. doi: 10.3748/wjg.v23.i14.2519
Published online Apr 14, 2017. doi: 10.3748/wjg.v23.i14.2519
Table 1 Demographic and preoperative clinical characteristics of 312 patients
Variables | Number of patients |
Age, median (range) | 66 (20-96) |
Sex | |
Male | 233 |
Female | 79 |
Diabetes mellitus | |
Absent | 273 |
Present | 39 |
Cardiac comorbidities | |
Absent | 217 |
Present | 95 |
Pulmonary comorbidities | |
Absent | 292 |
Present | 20 |
Preoperative symptoms | |
Absent | 172 |
Present | 140 |
Preoperative body mass index, mean ± SD | 21.9 ± 3.2 |
Tumor location | |
Entire | 8 |
Upper third | 68 |
Middle third | 120 |
Lower third | 116 |
Tumor size (mm) | |
< 50 | 176 |
≥ 50 | 136 |
UICC cT factor | |
cT1 | 0 |
cT2 | 150 |
cT3 | 95 |
cT4 | 67 |
UICC cN factor | |
cN0 | 157 |
cN1 | 93 |
cN2 | 53 |
cN3 | 9 |
UICC clinical stage | |
IB | 98 |
IIA | 71 |
IIB | 69 |
IIIA | 55 |
IIIB | 14 |
IIIC | 5 |
Table 2 Comparison between two subgroups according to the preoperative platelet-lymphocyte ratio
Variables | PLR < 0.71 (n = 154) | PLR ≥ 0.71 (n = 158) | P value |
Age, median (range) | 66 (20-86) | 66 (34-96) | 0.661 |
Sex | 0.434 | ||
Male | 112 | 121 | |
Female | 42 | 37 | |
Diabetes mellitus | 0.070 | ||
Absent | 140 | 133 | |
Present | 14 | 25 | |
Cardiac comorbidities | 0.785 | ||
Absent | 106 | 111 | |
Present | 48 | 47 | |
Pulmonary comorbidities | 0.021 | ||
Absent | 149 | 143 | |
Present | 5 | 15 | |
Preoperative symptoms | 0.838 | ||
Absent | 84 | 88 | |
Present | 70 | 70 | |
Preoperative body mass index, mean ± SD | 21.6 ± 3.3 | 22.2 ± 3.1 | 0.102 |
Tumor location | 0.673 | ||
Entire | 3 | 5 | |
Upper third | 32 | 36 | |
Middle third | 57 | 63 | |
Lower third | 62 | 54 | |
Tumor size (mm) | 0.043 | ||
< 50 | 78 | 98 | |
≥ 50 | 76 | 60 | |
UICC cT factor | 0.502 | ||
cT1 | 0 | 0 | |
cT2 | 69 | 81 | |
cT3 | 49 | 46 | |
cT4 | 36 | 31 | |
UICC cN factor | 0.633 | ||
cN0 | 75 | 82 | |
cN1 | 51 | 42 | |
cN2 | 24 | 29 | |
cN3 | 4 | 5 | |
UICC clinical stage | 0.823 | ||
IB | 45 | 53 | |
IIA | 37 | 34 | |
IIB | 32 | 37 | |
IIIA | 31 | 24 | |
IIIB | 7 | 7 | |
IIIC | 2 | 3 | |
Operative procedure | 0.669 | ||
Total gastrectomy | 52 | 57 | |
Distal gastrectomy | 102 | 101 | |
Splenectomy | 0.191 | ||
Absent | 128 | 122 | |
Present | 26 | 36 | |
Dissected lymph nodes, mean ± SD | 37.6 ± 15.8 | 38.7 ± 18.0 | 0.823 |
Operative time (min), mean ± SD | 233 ± 56 | 238 ± 74 | 0.720 |
Estimated blood loss (mL), median (range) | 237 (1-2350) | 245 (8-4267) | 0.491 |
Postoperative complications | < 0.001 | ||
Absent | 108 | 138 | |
Present | 46 | 20 |
Table 3 Predictive factors for grade 2 or higher complications according to the Clavien-Dindo system: Univariate and multivariable analyses
Variables | Univariate | Multivariable | ||||
Odds ratio | 95%CI | P value | Odds ratio | 95%CI | P value | |
Age (≥ 65 yr) | 1.26 | 0.73-2.23 | 0.410 | |||
Gender (male) | 4.22 | 1.88-11.3 | < 0.001 | 4.17 | 1.78-11.5 | < 0.001 |
Preoperative symptoms | 0.95 | 0.55-1.64 | 0.864 | |||
Diabetes mellitus | 1.14 | 0.49-2.45 | 0.755 | |||
Cardiac comorbidities | 1.81 | 1.02-3.18 | 0.041 | 1.55 | 0.83-2.87 | 0.166 |
Pulmonary comorbidities | 1.26 | 0.40-3.40 | 0.669 | |||
Body mass index (≥ 22) | 1.62 | 0.94-2.81 | 0.084 | |||
Preoperative PLR (< 0.71) | 2.94 | 1.66-5.35 | < 0.001 | 3.32 | 1.82-6.25 | < 0.001 |
Tumor location (lower third) | 0.62 | 0.34-1.11 | 0.107 | |||
Macroscopic tumor size (> 50 mm) | 1.19 | 0.69-2.05 | 0.534 | |||
UICC cT (cT4) | 1.30 | 0.67-2.69 | 0.457 | |||
UICC cN (cN1-3) | 1.75 | 1.01-3.08 | 0.045 | 1.69 | 0.93-3.08 | 0.083 |
Operative procedure (total gastrectomy) | 2.42 | 1.39-4.23 | 0.002 | 2.43 | 1.35-4.43 | < 0.001 |
- Citation: Inaoka K, Kanda M, Uda H, Tanaka Y, Tanaka C, Kobayashi D, Takami H, Iwata N, Hayashi M, Niwa Y, Yamada S, Fujii T, Sugimoto H, Murotani K, Fujiwara M, Kodera Y. Clinical utility of the platelet-lymphocyte ratio as a predictor of postoperative complications after radical gastrectomy for clinical T2-4 gastric cancer. World J Gastroenterol 2017; 23(14): 2519-2526
- URL: https://www.wjgnet.com/1007-9327/full/v23/i14/2519.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i14.2519